Search company, investor...

Founded Year

1995

Stage

PIPE - II | IPO

Market Cap

0.22B

Stock Price

215.86

About Oxford BioMedica

Oxford BioMedica is a company focused on cell and gene therapy, operating within the biotechnology and pharmaceutical sectors. The company offers end-to-end capabilities in the development and manufacturing of cell and gene therapies, specifically focusing on lentivirus, AAV, and adenoviral vectors. These services are primarily utilized by biotechnology and pharmaceutical companies. It was founded in 1995 and is based in Oxford, England.

Headquarters Location

Windrush Court Transport Way

Oxford, England, OX4 6LT,

United Kingdom

+44 (0) 1865 783 000

Loading...

Loading...

Oxford BioMedica Patents

Oxford BioMedica has filed 50 patents.

The 3 most popular patent topics include:

  • molecular biology
  • biotechnology
  • genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/14/2018

8/30/2022

Clusters of differentiation, Transcription factors, Immunology, Immune system, Oncology

Grant

Application Date

3/14/2018

Grant Date

8/30/2022

Title

Related Topics

Clusters of differentiation, Transcription factors, Immunology, Immune system, Oncology

Status

Grant

Latest Oxford BioMedica News

Global Viral Vector and Plasmid DNA Manufacturing Market Report 2023-2028: Industry Forecasted at $10.14 Billion by 2028, Dominated by Oxford Biomedica, Cognate BioServices, and Cell & Gene Therapy Catapult

Feb 20, 2024

has been showcased for its remarkable surge, valued at USD 5.49 billion in 2022, and is projected to continue along a trajectory of impressive growth. With the utilization of viral vectors and plasmid DNA becoming increasingly critical in the fields of gene therapy, vaccine production, and genetic engineering, stakeholders across biotechnology and biopharmaceutical landscapes are keen on the opportunities and forecasts within this sector. Amid the growing investment in cutting-edge gene therapy research and development, the market is set to experience a compound annual growth rate (CAGR) of 10.89% through 2028. This momentum is fueled by the ever-expanding potentials of gene therapy to address genetic disorders, rare diseases, and a burgeoning array of medical conditions requiring novel forms of treatment. Key Market Drivers The surge in activities within the market is attributable to an array of factors. From advancements in genetic engineering, represented by game-changing technologies like CRISPR-Cas9, to the biopharmaceutical industry's evolution resulting in efficient drug production techniques - a confluence of dynamism shapes the viral vector and plasmid DNA manufacturing ecosystem. Increased focus and capital injection into gene therapy's capabilities have catalyzed a broad scope of clinical applications that extends to the treatment of cancers and neurodegenerative disorders. Regulatory agencies have also been instrumental in fostering this environment by offering expedited approvals and supportive engagement in product development. Technological Advancements Technological strides in manufacturing modalities offer another pillar sustaining the market's robustness. Innovations in single-use bioreactors, cell culture media, and purification techniques are enhancing yield, purity, and the overall cost-effectiveness of viral vector and plasmid DNA production processes. These advancements ensure that the industry's pace matches the growing demand and complexity of gene therapy requirements. Key Market Challenges Nonetheless, the path to a fully actualized market is not devoid of hurdles. The high costs associated with complex manufacturing processes and the necessity to remain compliant with stringent regulatory standards add layers of financial pressure. Moreover, ethical questions tied to genetic manipulation and societal considerations about access and consent present ongoing dialogues that require conscientious attention. Regional Insights The largest market share is held by North America, a testament to the region's mature biopharmaceutical landscape. With a significant number of cutting-edge trials, deep investments, and a well-developed infrastructure for gene therapy development, North America sets the tone for global advancements in viral vector and plasmid DNA manufacturing. The report's comprehensive market analysis provides invaluable insights into product type trajectories and application trends, offering a detailed breakdown of the segments and regions driving growth within the Global Viral Vector and Plasmid DNA Manufacturing Market. Amid these extensive developments and future potentials, the industry stands on the cusp of transformational advancements that hold the key to breakthrough therapies and medical innovations. Key Attributes

Oxford BioMedica Frequently Asked Questions (FAQ)

  • When was Oxford BioMedica founded?

    Oxford BioMedica was founded in 1995.

  • Where is Oxford BioMedica's headquarters?

    Oxford BioMedica's headquarters is located at Windrush Court, Oxford.

  • What is Oxford BioMedica's latest funding round?

    Oxford BioMedica's latest funding round is PIPE - II.

  • Who are the investors of Oxford BioMedica?

    Investors of Oxford BioMedica include Serum Institute of India, Novo Holdings, University of Oxford, Molten Ventures and Spark Ventures.

  • Who are Oxford BioMedica's competitors?

    Competitors of Oxford BioMedica include Dicerna Pharmaceuticals, Stemline Therapeutics, Bio Design Lab, Mutabilis, DiaMedica and 7 more.

Loading...

Compare Oxford BioMedica to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

T
Targeson

Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the Targestarline of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson's agents can be readily targeted to the molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company's intellectual property aims to enable the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which aims to enable the user to verify that the therapeutic compound has been delivered to the intended site.

O
Orphagenix

OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.

A
Acureon Pharmaceuticals

Acureon Pharmaceuticals is a company focused on providing pharmaceutical products and healthcare financial solutions. The company offers a range of medical loans and financing options designed to assist individuals with healthcare expenses, regardless of their credit score. Acureon Pharmaceuticals primarily serves individuals seeking financial assistance for medical-related costs. It is based in Berwyn, Pennsylvania.

T
Targeted Cell Therapies

Targeted Cell Therapies is an early-stage biopharmaceutical company focused on the development of biotherapeutics for a variety of human diseases. The company specializes in a technology platform that enables the conversion of injectable biologics into oral medications, simplifying the delivery process and potentially improving patient quality of life. It is based in Worcester, Massachusetts.

W
WesaGen

WesaGen is a biopharmaceutical company founded by Dr.Mustapha Abdelouahed, Ph.D., with expertise in Immunology, Hemostasis, Coagulation, Cell & Molecular Biology of Vessels, and Dr. Jack Lawler, Ph.D., Professor at Harvard Medical School. WesaGen is engaged in the near-term development of technologies to diagnose type 2 heparin-induced thrombocytopenia (or HIT, a life-threatening condition); the development of a line of and potent anti-angiogenic therapeutic drugs to treat cancer; and research and development based on a new nanoscale drug delivery platform technology.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.